Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
New findings from I. Chirivella and co-researchers in the area of breast cancer described
April 16th, 2009
"To evaluate the dose-response effect of an adjuvant anthracycline-based non-taxane chemotherapy in early breast cancer patients. This was a retrospective database analysis," scientists in Valencia, Spain report. "Selection criteria included patients treated for early breast cancer from years 1980 to 2000 with an adjuvant anthracycline-based non-taxane chemotherapy. The delivery of chemotherapy was assessed through the number of delayed cycles, the number of delayed days and the relative dose intensity (RDI) administered (a parts per thousand yen85%, < 85%). Seven hundred and ninety-three breast cancer patients were included. The Kaplan-Meier disease-free survival...
Source: Women's Health Weekly (2009-04-16)
|
